Anixa Biosciences (ANIX) Interest Expenses (2012 - 2026)
Anixa Biosciences' (ANIX) quarterly Interest Expenses came in at $1.5 million in Q2 2026, up 111.99% YoY from $692000.0 in Q2 2025, and down 99.98% on a QoQ basis from $7.4 billion in Q4 2025.
Anixa Biosciences (ANIX) Interest Expenses (2012 - 2026) Analysis & Trends
Anixa Biosciences (ANIX) has 15 years of Interest Expenses data on file, last reported at $1.5 million in Q2 2026.
- Quarterly Interest Expenses rose 111.99% year-over-year to $1.5 million in Q2 2026, while the trailing twelve-month figure through Apr 2026 was $1.5 million (up 111.99% YoY) and the FY2025 annual result came in at $7.4 billion, up 265.73% from the prior year.
- Interest Expenses slipped to $1.5 million in Q2 2026, from $7.4 billion in the prior quarter.
- In the past five years, Interest Expenses ranged from a high of $34.5 billion in Q4 2023 to a low of $582000.0 in Q2 2024.
- A 5-year average of $4.2 billion and a median of $2.3 million in 2023 frame the typical range for Interest Expenses.
- Annual changes were most pronounced in 2022 — Interest Expenses jumped 9108307592.31% — and 2024, when it sank 99.89%.
- Tracing ANIX's Interest Expenses over 5 years: stood at $29.6 billion in 2022, then advanced by 16.55% to $34.5 billion in 2023, then slumped by 99.89% to $37.8 million in 2024, then jumped by 19432.63% to $7.4 billion in 2025, then sank by 99.98% to $1.5 million in 2026.
- The last three Interest Expenses figures came in at $1.5 million (Q2 2026), $7.4 billion (Q4 2025), and $1.7 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 11.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 39.74 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 82.05 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -4.89 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 20.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 93.62 Mn |
| 10 | Anixa Biosciences | 123.62 Mn | 123.62 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 30, 2026 | 1.47 Mn |
| Apr 30, 2026 | 1.47 Mn |
| Oct 31, 2025 | 7.37 Bn |
| Oct 31, 2025 | 7.37 Bn |
| Jul 31, 2025 | 1.71 Mn |
| Jul 31, 2025 | 1.71 Mn |
| Apr 30, 2025 | 692,000.00 |
| Apr 30, 2025 | 692,000.00 |
| Jan 31, 2025 | 1.09 Mn |
| Jan 31, 2025 | 1.09 Mn |
| Oct 31, 2024 | 37.75 Mn |
| Oct 31, 2024 | 37.75 Mn |
| Jul 31, 2024 | 1.51 Mn |
| Jul 31, 2024 | 1.51 Mn |
| Apr 30, 2024 | 582,000.00 |
| Apr 30, 2024 | 582,000.00 |
| Jan 31, 2024 | 9.24 Mn |
| Jan 31, 2024 | 9.24 Mn |
| Oct 31, 2023 | 34.50 Bn |
| Oct 31, 2023 | 34.50 Bn |